The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design

por Haws, Robert M., Gordon, Gregory, Han, Joan C., Yanovski, Jack A., Yuan, Guojun, Stewart, Murray W.
Publicado 2021

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with typ...

por Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, Marc
Publicado 2015